December 20, 2021Now, our company received the Notification of Approval of Supplementary Application for Repaglinide Tablets issued by the State Medical Products Administration (Notification No. : 2021 B04618). After ...view
August 4, 2022Recently, the Beijing Municipal Drug Administration and Beijing Municipal Health Commission issued the "notice on the outstanding Performance of units and individuals in the monitoring of adverse...view
March 7, 2023Recently, Zhejiang Haichang Pharmaceutical Co., Ltd., a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received a registration certificate for its active pharmaceutical ingredient product from ...view
July 5, 2022Young and middle-aged people face more problems in life, work, and emotion. So they are prone to anxiety, which can lead to high blood pressure. Therefore, it is important to control and relieve the a...view
September 21, 2023Beilu Pharmaceutical's subsidiary, Zhejiang Hichi Pharmaceutical, has recently obtained the certificate of registration for Iohexol API from the Ministry of Food and Drug Safety in Korea.This regi...view
Call us on: 
Email Us: 
No.3 Shuiyuan West Road, Miyun District, Beijing, China 
EN
jp 
fr 
de 
es 
ru 
pt 
ar 
